Premium
Anti‐myeloma activity of pamidronate in vivo
Author(s) -
Dhodapkar Madhav V.,
Singh Joginder,
Mehta Jayesh,
Fassas Athanasios,
Perlman Martin,
Munshi Nikhil C.,
Barlogie Bart
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00976.x
Subject(s) - plasmacytosis , multiple myeloma , medicine , bone marrow , bone disease , plasma cell , bone mineral , in vivo , immunopathology , osteoporosis , gastroenterology , biology , microbiology and biotechnology
Two patients with progressive myeloma were treated with pamidronate disodium every 2‐4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and >50% reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti‐myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.